{"id":33183,"date":"2024-07-03T12:11:45","date_gmt":"2024-07-03T12:11:45","guid":{"rendered":"https:\/\/ibima.eu\/the-cardiovascular-safety-of-cagrilintide-2-4-mg-s-c-in-combination-with-semaglutide-2-4-mg-s-c-cagrisema-2-4-mg-2-4-mg-s-c-once-weekly-in-participants-with-obesity-and-established-cardiovascular\/"},"modified":"2024-07-03T12:11:45","modified_gmt":"2024-07-03T12:11:45","slug":"the-cardiovascular-safety-of-cagrilintide-2-4-mg-s-c-in-combination-with-semaglutide-2-4-mg-s-c-cagrisema-2-4-mg-2-4-mg-s-c-once-weekly-in-participants-with-obesity-and-established-cardiovascular","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/the-cardiovascular-safety-of-cagrilintide-2-4-mg-s-c-in-combination-with-semaglutide-2-4-mg-s-c-cagrisema-2-4-mg-2-4-mg-s-c-once-weekly-in-participants-with-obesity-and-established-cardiovascular\/","title":{"rendered":"The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg\/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease"},"content":{"rendered":"
FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – NOVO NORDISK A\/S<\/p>","protected":false},"excerpt":{"rendered":"
FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – NOVO NORDISK A\/S<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2266],"tags":[],"acf":[],"yoast_head":"\n